

WHAT IS CLAIMED IS:

5

1. An immunogenically active component which comprises a member selected from the group consisting of merozoite antibody inducing, inactivated *Sarcocystis neurona* cells; tachyzoite antibody inducing, inactivated *Neospora hughesi* cells; a merozoite or tachyzoite antibody inducing antigen derived from said cells; DNA derived from said cells capable of inducing a merozoite or tachyzoite antibody immune response; and a mixture thereof.

10
15

2. The component according to claim 1 which comprises inactivated *Sarcocystis neurona* cells; an antigen derived from said cells; DNA derived from said cells; or a mixture thereof.

20

3. The component according to claim 1 which comprises inactivated *Neospora hughesi* cells; an antigen derived from said cells; DNA derived from said cells; or a mixture thereof.

25

4. The component according to claim 1 wherein said active component is present in sufficient quantity to provide at least 1×10^4 inactivated cells per unit dose form.

5. A vaccine composition which comprises an effective immunizing amount of the immunogenically active component of claim 1, a pharmacologically acceptable carrier; and optionally an immunogenically stimulating
5 adjuvant.

6. The vaccine composition according to claim 5 wherein said active component is present in sufficient quantity to provide at least 1×10^4 inactivated cells per
10 unit dose form.

7. The vaccine composition according to claim 5 wherein said active component is present in sufficient quantity to provide at least 1×10^6 inactivated cells per
15 unit dose form.

8. The vaccine composition of claim 2 wherein said active component is present in an amount sufficient to produce a merozoite inducing serum neutralizing antibody
20 response which is protozocidal.

9. The vaccine composition of claim 3 wherein said active component is present in an amount sufficient to produce a tachyzoite inducing serum neutralizing antibody
25 response which is protozocidal.

10. The vaccine composition according to claim 5 wherein the immunogenically stimulating adjuvant is present at about 1% to 50% wt/wt.

11. The vaccine composition according to claim 10 wherein said adjuvant is present at about 5% to 20% wt/wt.

5 12. The vaccine composition according to claim 10 wherein said active component comprises inactivated *Sarcocystis neurona* cells.

10 13. The vaccine composition according to claim 12 wherein said adjuvant is a metabolizable oil.

15 14. The vaccine composition according to Claim 13 wherein the pharmacologically acceptable carrier is a balanced salt solution.

15 15. A vaccine composition for the prevention or amelioration of EPM disease in equines comprising,

- a first immunogenically active component selected from the group consisting of merozoite antibody inducing, 20 inactivated *Sarcocystis neurona* cells; a merozoite antibody inducing antigen derived from said cells; DNA derived from said cells capable of inducing a merozoite antibody immune response; or a mixture thereof;

- a second immunogenically active component selected from 25 the group consisting of tachyzoite antibody inducing, inactivated *Neospora hughesi* cells; a tachyzoite antibody inducing antigen derived from said cells; DNA derived from said cells capable of inducing a tachyzoite antibody immune response; or a mixture thereof;

30 - a pharmacologically acceptable carrier; and optionally an immunogenically stimulating adjuvant.

16. The vaccine composition according to claim 15
wherein said first immunologically active component
comprises inactivated *Sarcocystis neurona* cells and said
5 second immunologically effective component comprises
inactivated *Neospora hughesi* cells.

17. The vaccine composition according to claim 15
wherein said first immunologically active component is
10 present in an amount sufficient to produce a merozoite
inducing serum neutralizing antibody response which is
protozocidal, and wherein said second immunologically
active component is present in an amount sufficient to
produce a tachyzoite inducing serum neutralizing antibody
15 response which is protozocidal.

18. A method for the prevention or amelioration of
EPM disease in equines which comprises administering to
said equine an immunogenically active component which
20 comprises a member selected from the group consisting of
merozoite antibody inducing, inactivated *Sarcocystis neurona* cells; tachyzoite antibody inducing, inactivated *Neospora hughesi* cells; a merozoite or tachyzoite antibody inducing antigen derived from said cells; DNA
25 derived from said cells capable of inducing a merozoite or tachyzoite antibody immune response; or a mixture thereof.

19. A method for the prevention or amelioration of
30 EPM disease in equines which comprises administering to
said equine a vaccine composition which comprises,

- an effective immunizing amount of an immunogenically active component which comprises a member selected from the group consisting of merozoite antibody inducing, inactivated *Sarcocystis neurona* cells; tachyzoite antibody inducing, inactivated *Neospora hughesi* cells; a merozoite or tachyzoite antibody inducing antigen derived from said cells; DNA derived from said cells capable of inducing a merozoite or tachyzoite antibody immune response; or a mixture thereof; and

10 - a pharmacologically acceptable carrier; and optionally an immunogenically stimulating adjuvant.

20. A method for the prevention or amelioration of EPM disease in equines which comprises administering to

15 said equine a vaccine composition which comprises,

- a first immunogenically active component selected from the group consisting of merozoite antibody inducing, inactivated *Sarcocystis neurona* cells; a merozoite antibody inducing antigen derived from said cells; DNA derived from said cells capable of inducing a merozoite antibody immune response; or a mixture thereof;

- a second immunogenically active component selected from the group consisting of tachyzoite antibody inducing, inactivated *Neospora hughesi* cells; a tachyzoite antibody inducing antigen derived from said cells; DNA derived from said cells capable of inducing a tachyzoite antibody immune response; or a mixture thereof;

- a pharmacologically acceptable carrier; and optionally an immunogenically stimulating adjuvant.

21. The method according to claim 18 wherein said vaccine is administered parenterally.

22. The method according to claim 18 wherein said
5 vaccine is administered intramuscularly.

23. A method for the cell culture propagation of *Sarcocystis neurona* or *Neospora hughesi* protozoan parasite which comprises:

10 a) growing a monolayer of cells having a confluence of 80%-100%;
 b) refeeding said cells with supplemented growth media;
 c) inoculating said cells with merozoites or
15 tachyzoites;
 d) holding the inoculated cells for 4-12 days;
 e) decanting the supplemented growth media from the inoculated cells; and
 f) refeeding said cells a second time with
20 supplemented growth media.

24. The method according to claim 23 wherein the cells are selected from the group consisting of Equine Dermal cells; Maiden Darby Bovine Kidney cells; African Green Monkey Kidney cells; Canine Monocyte cells; Mouse Monocyte cells; Fetal Rhesus Monkey Kidney cells; Feline Kidney cells, Maiden Darby Canine Kidney cells; and Baby Hamster Kidney cells.

25. The method according to claim 23 wherein the cells are Equine Dermal cells or African Green Monkey Kidney cells.

053405-00234